Poly Medicure Limited
Momentum (71/100) does the heavy lifting; valuation (25/100) is the drag.
Fair valueOvervaluedOur blended model reads Poly Medicure Limited as a Hold at 45/100. We put fair value near ₹1,249.56; at ₹1,678.5 that leaves roughly 26% downside, so the stock screens overvalued by 26%. On 52.1x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 21% below its 52-week high of ₹2,118.08 and 41% above the low of ₹1,191.1. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. The average analyst target of ₹1,607.17 implies about 4% downside across 6 analysts. It clears 7 of 13 investability checks, with durability 60, valuation 42 and momentum 71 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹999.65.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-20.75% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 10.8%
- Pass: Low debt (D/E < 0.5): 0.11x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 21%
- Fail: Earnings growing: -27%
- Pass: Net margin ≥ 10%: 17.2%
- Pass: Current ratio > 1.5: 3.37
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 14.33
- Fail: Piotroski ≥ 7: 2/9
Quarterly results
Annual financials
Shareholding
- Promoter67.9%
- Institutions21.8%
- Public & other10.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (17.2%).
- Financially solid — Altman Z 14.33.
Opportunities
- Revenue growing (21% YoY).
Bear case
Weaknesses
- Weak Piotroski score (2/9).
Threats
- Earnings contracting year on year.
- Trades ~26% above our estimated fair value.
About Poly Medicure Limited
Poly Medicure Limited manufactures and sells medical devices in India and internationally. Its product portfolio includes infusion therapy items such as I.V. infusion sets, extension lines, needle-free connectors, flow regulators, burette sets, three-way stop cocks, vial access spikes, transfer spikes, and arterial blood collection devices, alongside critical care products including arterial cannulas and mini mid-line catheters.
Poly Medicure Limited — frequently asked questions
Is Poly Medicure Limited a buy, hold or sell?
StocksWizard currently rates Poly Medicure Limited (POLYMED) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Poly Medicure Limited's fair value?
Our blended DCF and relative-valuation model estimates Poly Medicure Limited's fair value at about ₹1,249.56, versus a current price of ₹1,678.5 — roughly 26% downside. On that basis the stock looks overvalued by 26%.
Is Poly Medicure Limited financially healthy?
Poly Medicure Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has Poly Medicure Limited's share price performed?
Poly Medicure Limited is up 11% over three months, and last traded at ₹1,678.5. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.